We review our 24-year experience with extrapleural pneumonectomy (EPP) in the treatment of epithelioid malignant pleural mesothelioma (MPM). Background: Recent publications, particularly the MARS (Mesothelioma and Radical Surgery) feasibility study by Treasure et al, have questioned the safety and efficacy of EPP for MPM. Methods: An institutional review board-approved, prospective, single-center database was retrospectively reviewed. Descriptive statistics and Kaplan-Meier analysis of overall survival are reported. Results: From 1988 to 2011, a total of 529 patients with epithelioid MPM underwent complete resection by EPP as part of a multimodality strategy. Among these, 131 (25%) were women, and the median age was 59 (range, 17-79) years. Median postoperative hospital stay was 10 (range, 1-101) days. Twenty-six patients (5%) experienced 30-day or in-hospital mortality. Median overall survival was 18 months, with 1-, 3-, 5-, and 10-year survival rates of 67%, 28%, 14%, and 4%, respectively. Outcome by pathologic lymph node status (N, median overall survival) was N0: 224, 26 months; N1: 118, 17 months; N2: 181, 13 months; N3: 5, 7 months; Nx: 1, not evaluable. Conclusions: EPP has evolved as an effective method for macroscopic complete resection. This study confirms that lymph node status is significantly correlated with overall survival in patients with epithelioid MPM undergoing EPP and suggests that those with simultaneous involvement of N1 and N2 stations are at increased risk. This observation underscores the need for thorough staging of both N1 and N2 stations and has implications for revision of MPM staging criteria.
are palliative in nature, with median survival of approximately 7 to 12 months. 1, 2 For selected patients with disease confined to the ipsilateral hemithorax, however, surgical resection, combined with systemic or intracavitary chemotherapy, radiation therapy, and/or other local modalities, has been offered with reports of more optimistic outcomes. The operative procedures most commonly used in multimodal approaches include the following: extrapleural pneumonectomy (EPP), involving en bloc resection of the lung, pericardium, diaphragm, visceral, and parietal pleura; pleurectomy/decortication (P/D), involving resection of the visceral and parietal pleurae leaving the lung, pericardium, and diaphragm intact; and extended P/D, involving pleurectomy with preservation of the lung and resection of pericardium and/or diaphragm. 3 Three main histologic subtypes are distinguished-epithelioid, biphasic, and sarcomatoid. 4 These subtypes differ significantly in terms of clinical behavior, response to therapy, and overall survival, 5 prompting the authors to advocate for separate or annotated staging and outcome reporting 6 and to focus this study on the epithelioid subtype.
Although retrospective reports of case series and early-phase prospective trials suggest benefit from surgery for selected patients treated at experienced centers, the relatively small number of patients presenting with resectable MPM, combined with patient and surgeon preference, has thus far precluded an adequately powered randomized trial. A randomized study would be particularly informative in the case of EPP, which involves the largest degree of resection and is usually applied to the most locally advanced among resectable tumors. The MARS (Mesothelioma and Radical Surgery) feasibility trial, however, indicated a low likelihood of randomizing an adequate number of patients to power such a trial. 7 The authors argued that the small number of patients randomized in the feasibility study provided evidence that EPP is associated with excessive morbidity and mortality, lacks efficacy, and should be abandoned. This report provoked a counterpoint response, 8 a published statement by International Mesothelioma Interest Group surgeons, 9 and ongoing debate within the international MPM treatment community. It remains unlikely that an adequately powered randomized trial will be conducted. Therefore, we report our experience with EPP-based multimodality therapy in 529 patients with pathologically proved epithelioid MPM over a 24-year period, with emphasis on long-term outcome.
(MCR) usually can be obtained. Specific indications for EPP thus have included clinical evidence of tumor invasion of lung parenchyma, interlobar fissures, diaphragm, and pericardium, all of which complicate MCR via pleurectomy.
Preoperative surgical staging has also evolved during the study period. The prognostic significance of nodal metastasis was described in 1993. 10 Cervical mediastinoscopy began to be performed routinely in 2004, after cisplatin-pemetrexed was accepted as a standard chemotherapy regimen for MPM. 2 Since that time, patients found to have mediastinal metastases on mediastinoscopy have undergone neoadjuvant chemotherapy before reevaluation for surgery.
With institutional review board approval, a patient data registry was established in 2005. Data in this registry have been abstracted retrospectively for patients treated before 2005 and prospectively for patients treated since then. Data derived from source documents in the medical record are entered into a custom client-server relational database using on-screen forms for all patients who undergo resection. Follow-up data are obtained via outpatient clinic records and/or contact with treating physicians. Patient death is documented in the registry on the basis of notifications appearing in the electronic medical record or via the Social Security Death Index or obituaries. This data registry was examined for the current study to identify all patients who underwent EPP through December 31, 2011, with epithelioid subtype tumors identified by final pathologic analysis.
Patient data extracted from the registry included sex, age, vital status, follow-up interval, and length of hospitalization after EPP. Tumor parameters included laterality and pathologic involvement with lung parenchyma, interlobar fissures, diaphragm, and regional lymph nodes. Staging parameters included cervical mediastinoscopy and tissue biopsy. Length of hospital stay was calculated as the interval from the date of surgery to the date of discharge. Overall survival (OS) was calculated as the interval from the date of surgery to the date of death or most recent contact.
Descriptive statistics, Kaplan-Meier survival functions, logrank comparisons, and Cox proportional hazards modeling were applied to characterize the patient and tumor characteristics in relation to the OS for this cohort. For analysis of lymph node status, indicator variables were created using N0 as reference (hazard ratio = 1.0). Statview software (version 4.5; Abacus Concepts, Piscataway, NJ) was used for all calculations and plots. Two-sided P values less than 0.05 were considered significant.
RESULTS
Between 1988 and 2011, a total of 1258 patients recorded in the registry underwent surgery for MPM, of which 832 were EPP and the remainder were P/D, extended P/D, or partial pleurectomy. Among patients undergoing EPP, 529 were found upon final pathologic examination to have epithelioid subtype tumors, and these constitute the current cohort. Two hundred eighty-one patients (53%) underwent right-sided EPP. One hundred thirty-one patients (25%) were women. The median age was 59 (range, 17-79) years. Among these patients, 469 (89%) are known to have died, 22 (4%) were lost to follow-up, and 38 (7%) are alive in active follow-up. The median length of hospital stay was 10 days, with a range of 1 to 101 days. Length of hospital stay above or below the median was not associated with OS duration (P = 0.1263). Twenty-six patients (5%) died within 30 days of the procedure or during their postoperative hospitalization. The 90-day mortality rate was 8% (44/529 patients).
Five hundred two patients (95%) had a pleural biopsy before EPP that was diagnostic of MPM. Of these, 485 (97%) were concordant with the final diagnosis of epithelioid MPM and 17 (3%) were called biphasic. The remaining 27 patients had MPM diagnosed on cytology without determination of subtype and/or had a nondiagnostic tissue biopsy. Cervical mediastinoscopy was performed for 196 patients (37%), with nodal metastasis detected in 27 patients (14%). Seventy-one patients (13%) underwent induction chemotherapy before resection, and 218 patients (55%) underwent hyperthermic intraoperative intracavitary chemotherapy.
Upon pathological examination, tumor invasion of lung parenchyma was documented in 311 cases (59%), of interlobar fissures in 426 cases (81%), of pericardium in 314 cases (59%), and/or of diaphragm in 334 cases (63%). American Joint Commission on Cancer (AJCC) staging information is provided in Table 1 . Lymph node status was N0 for 43% of patients, N1 for 22% of patients, N2 for 34% of patients, N3 for 1% of patients, and Nx for 1 patient. In addition to maximal efforts to stage N2 disease, N1 nodes were removed and analyzed in 525 patients (99%) as part of a standardized pathologic protocol for EPP specimens. One hundred thirty-six patients (26%) with N2 involvement also had N1 nodal involvement, and 45 (9%) had N2-only involvement. Stage distribution was as follows: stage I, 3%; stage II, 10%; stage III, 65%; and stage IV, 22%. Two patients could not be staged as a result of no tumor being found (pT0) and unknown lymph node status (Nx), respectively.
Median OS for the entire cohort was 18 months ( Fig. 1 ). T1  21  4  T2  105  20  T3  290  55  T4  111  21  N0  226  43  N1  116  22  N2  181  34  N3  5  1  Nx  1  <1  Stage I  14  3  Stage II  55  10  Stage III  343  65  Stage IV 115 22 sex were significantly prognostic, whereas tumor laterality and hospital length of stay were not. Patient OS was correlated with pathologic AJCC tumor stage ( Fig. 2 ). Lymph node status was prognostic, with increasing N classification level associated with decreasing median OS and increasing hazard for all-cause death ( Fig. 2A ). When N2 cases were separated into 2 subgroups, representing those with simultaneous N1 metastases and those without, it was further revealed that patients with N2-only or N1-only metastasis had similar, more favorable survival functions than patients with simultaneous N2 and N1 metastases ( Fig. 2B ).
DISCUSSION
This retrospective study describes the long-term outcome of a large cohort of patients with epithelioid MPM who underwent EPP. The procedure was generally well-tolerated, with most patients requiring 1 to 2 weeks in the hospital postoperatively. Most perioperative complications were manageable or self-limiting such that length of stay extending beyond the median 10 days was not associated with reduced overall survival duration. Operative mortality was 5%, which is reasonable in this elderly, often comorbid, cohort comprising 87% stage III and IV disease. These findings support EPP as a safe and effective component of an evolving multimodality paradigm for MPM confined to one hemithorax.
The decision as to the appropriate procedure for an individual patient with apparently resectable MPM at our institution is made with consideration of disease distribution and patient fitness. MCR, whether by EPP or P/D, is part of a 2-step therapeutic strategy based on surgical removal of macroscopic tumor, followed by adjuvant local and systemic treatment modalities to control micrometastatic disease. Generally, P/D is preferred for tumors apparently confined to the pleura, as it affords an MCR while sparing the lung. 11 Our specific indications for EPP thus have included clinical evidence of tumor invasion of lung parenchyma, interlobar fissures, diaphragm, and pericardium, which complicate MCR via pleurectomy. Extended P/D or partial pleurectomy (which leaves macroscopic tumor unresected) is sometimes applied in patients who would otherwise require EPP for MCR but lack fitness to tolerate pneumonectomy.
This study reemphasizes the well-established prognostic role of lymph node status in epithelioid MPM. 6, 10, 12 There is evidence that its prognostic impact is relatively less pronounced for patients with biphasic subtype tumors 13 and that lymph node metastasis is only rarely associated with sarcomatoid subtype tumors (unpublished observations). Unlike non-small cell lung cancer, N2 metastasis in MPM may develop independently of N1 involvement in approximately 40% of cases. [14] [15] [16] Nodal classification for non-small cell lung cancer staging is based on the pattern of pulmonary lymphatic drainage, whereas for MPM, direct metastasis to N2 stations, bypassing N1 nodes, is possible via drainage from the diaphragmatic pleura directly to the mediastinal lymphatic chain. 17 It is unlikely that the observation of N2 without associated N1 resulted from incomplete sampling of N1, because meticulous dissection with N1 along with sampling and microscopic examination of nodes was accomplished in 99% of cases.
The current edition of the staging system does not distinguish between N1 and N2 metastasis in determining stage. The observations in the current study, namely, that increasing N classification level is associated with a progressively worse prognosis and simultaneous involvement of N1 and N2 lymph node stations portends worse prognosis than either N1 or N2 involvement alone, should be of interest as the AJCC staging system is revised.
These findings also reinforce the point that preoperative assessment of lymph node status should be helpful in selecting patients for appropriate therapy. Cervical mediastinoscopy began to be performed routinely in our program in 2004, with the advent of an available standard neoadjuvant chemotherapy regimen. Patients with mediastinal metastases undergo neoadjuvant chemotherapy before reevaluation for surgery. The sensitivity of this procedure, alone, for determining nodal status is low. However, given the inaccessibility of relevant nodal stations, it is reasonable to consider whether endoscopic ultrasonography, endobronchial ultrasonography, thoracoscopy, or other procedures should be routinely performed as part of a surgical staging strategy. 18, 19 The limitations of this study include those biases common to all retrospective, single-institution reviews. Furthermore, the patients have been treated in a multimodal fashion using strategies and regimens that have evolved over a 24-year time span. In addition, patients completed their treatment regimens to varying degrees. These shortcomings are balanced somewhat by the completeness of the data set, the prospective nature of much of the data, and the size of the cohort in this rare disease. The exclusive focus on the epithelioid subtype also mitigates some of the interpretive issues that plague many studies of outcome in MPM.
CONCLUSIONS
This study supports the safety and feasibility of a 2-step approach to treatment: EPP with MCR, followed by eradication of micrometastatic disease by adjunctive local and systemic therapy. Also highlighted is the importance of thorough staging of both the N1 and N2 stations. Combined involvement of N1 and N2 has a worse prognosis than involvement of N2 or N1 stations separately. This novel finding has implications for the revision of the MPM staging criteria. The goal of future work should be better patient selection and more effective agents for controlling micrometastatic disease.
DISCUSSANTS D. Jones (New York, NY):
You have shared with us today one of, if not perhaps, the largest series with EPP for epithelial and malignant mesothelioma. As we all know, this is a devastating disease, affecting, as you mentioned, slightly more than 3000 patients in the United States annually.
I think this prognosis is poor in large part due to a limited understanding of the biology of the disease and the difficulty in identifying targetable mutations or gene amplifications. In addition, the ability of mesothelioma to not only infiltrate the parietal and visceral pleurae but also the diaphragm, the pericardium, and the lymph nodes makes achieving an R0 resection particularly challenging.
You have had a lifelong interest in this disease. Today's presentation is a highlight of decades of observations made in the surgical care of these challenging patients by you and your colleagues at the Brigham. There are 2 important observations that have come to light today. These are the nuanced relevance of nodal staged as an important prognostic variable and the suggestion that the identification of this may have relevance to future iterations of the AJCC staging system. I have 2 questions for you. First, similar to locoregionally advanced non-small cell lung cancer, the present of N2 disease in malignant mesothelioma is frequently used to initially offer patients induction therapy. What upfront nodal sampling strategies do you recommend at this point, and do all patients currently undergo 1 or more of these invasive nodal staging assessments?
The second and last question is whether you have any data on whether the presence of either N2 disease alone or combined N1/N2 disease is predictive of the ability of the surgeon to obtain either an R0 or R1 resection versus leaving gross disease or an R2 resection. that, based on our data that we published in the journal Cancer a couple of years ago, the higher the node station from inferior to superior access, the poorer the prognosis. So, we do go after lymph nodes with mediastinoscopy, endobronchial ultrasonography, and often the PET scan is helpful in steering us in the right direction.
Your second question in terms of induction therapy, there has been a study conducted several years ago now of an induction strategy. The group in Zurich is performing induction therapy routinely. We have strayed away from this in the sense that many patients will have difficulty with the chemotherapy and then have, obviously, ruled themselves out to be a candidate for EPP or radical pleurectomy.
We have focused on locoregional disease, intraoperative heated chemotherapy. We have progressed through a series of phase 1 and 2 protocols and have now just finished a doublet treatment strategy of platinum, gemcitabine for a 1-hour intraoperative lavage. So, we have focused more on perioperative induction, locoregional therapy, if you will, or peri-induction therapy, as the term is used now.
At the present time, other than high N2 disease, there is really no predictor of resectability from a standpoint of nodal status. Magnetic resonance imaging is the most helpful in our institution to help us rule out transmediastinal or transdiaphragmatic involvement. Obviously, pain on presentation is a very, very bad sign, with chest wall invasion, usually diffuse precluding resection.
DISCUSSANTS

T.K. Rosengart (Houston, TX):
It appears from your data clearly that early detection is going to play an important role, at least for the time being, in terms of getting early disease. Do you have any thoughts in terms of whether computed tomography or any other modality is foreseeable as a modality for early detection?
Response From D.J. Sugarbaker:
The problem of early screening has been around for a long time. Back in the day, when I was younger at the Brigham, I had a lot of dealings with the refrigeration workers union and some shipbuilding when it was still going on, particularly down in Quincy at the shipyard, and the insulation folks.
Other than a chest radiograph that would demonstrate the presence of fluid at the costophrenic angle, there really isn't a good screening system. The serologic, mesothelin, osteopontin, that have been hopeful in the early stages really haven't panned out.
Computed axial tomography, I think if there's fluid on the chest radiograph is probably still the best and easiest and cheapest way to do it. We recommend it annually.
DISCUSSANTS
C. Deschamps (Burlington, VT):
Can you comment on the length of the study? Everything has changed. Mortality has changed, the operation has changed, the timing of the neoadjuvant therapy. And I'm talking about the mortality now, what do you think has made the most difference in terms of the low mortality rate that you are now achieving compared with 1988, which I remember was not that great?
Response From D.J. Sugarbaker:
I think the focus on this particular procedure has kept an evolution going on. I would say probably one of the most important factors, as far as I can tell, would be the technique of pericardial reconstruction and the technique of diaphragmatic reconstruction. In the early days, we had difficulty with herniation of the intestinal contents into the ipsilateral chest, with mediastinal compression and respiratory failure, herniation of the myocardium through the pericardial aperture sometimes also caused difficulty.
I would say the second thing is perioperative care. At our institution, we have obviously a lot of experience. As our postoperative team began to get more and more experience, we began to look at different routine use of the Swan-Ganz catheter during the procedure etc. I think that's had a big impact. Finally, I think patient selection has been very important with mediastinoscopy and magnetic resonance imaging.
DISCUSSANTS
V. Rusch (New York, NY):
It's very reassuring to see that the results that you've presented here are corroborated by experience in other centers of excellence, including Memorial Sloan-Kettering in New York, the University of Toronto, University of Zurich, and so forth. The data that you've presented in terms of nodal disease will be very helpful as external validation for planned revisions to the mesothelioma staging system in the upcoming eighth edition of the AJCC and UICC staging manuals.
I have 2 questions for you to comment on. First, I think this disease is a little bit similar to esophageal cancer in that T often correlates with N. In prospective multimodality trials that we've conducted at Sloan-Kettering, you can often make that decision about whether or not to use induction therapy for locally advanced disease based on T status, even without the N information. I would be interested if you have any analyses from this experience in that regard.
Second, as you know, there's tremendous skepticism, particularly in the United Kingdom, about doing EPP under any circumstance. However, similar to your experience, the IASLC database analysis has shown a favorable outcome for stage I patients after EPP. Any comment on that?
Response From D.J. Sugarbaker:
In terms of T status, I think, at our institution, we are, if you will, drifting away from a focus on T staging. We are focusing more on tumor volume, in the sense that tumor volume in mesothelioma has been shown way back with * Dr Pass' work and more recently with * Dr Gill's publication of our large series to be, really, the most important predictor of long-term survival.
In terms of the British and those in the United Kingdom and mesothelioma, they are, I think, at the present time, following data in their publication of the MARS trial, which was an attempt to randomize patients to EPP or not. Under scrutiny, the trial really doesn't hold up at all. I think any conclusions based on 28 patients, which I think was the total number, are probably invalid.
So, I think that the concept and the real strategy that needs to be moved forward is not so much which operation you do, pleurectomy or EPP, you do the operation; you need to start with complete cytoreduction and then move to the next, which is what sort of locoregional or systemic therapy are you going to use, biologics targeted, etc.
I think what we have shown today is that we can get the first part done with an EPP. Even in late-stage disease, we can get to R0 resection. And then let's work on the next part. That's kind of the approach I would take.
DISCUSSANTS C. Wright (Boston, MA):
I have 2 questions. One focusing on your excellent low perioperative mortality rate of only 5%, although your 1-year survival rate was down to 67%. As you know, with big operations, there's been several publications recently in thoracic surgery focusing on 90-day mortality and that we underestimate the morbidity and mortality to Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. our patients. For example, Sloan-Kettering just reported its results of a 3% perioperative mortality rate and a 12% perioperative mortality rate with EPP, which is then very close to your rate of 14% for 5-year survival, which gives you pause. I just wonder if you could tell us what your 90-day mortality is for this big operation.
Then I wanted to hone in further on what Claude said. You showed many years ago that lymph nodes are important and N2 lymph nodes are especially a poor prognostic factor. Presumably, you changed your technique in your patient selection many years ago and started to try to eliminate those patients. Are you doing better? Did you do a subset analysis when you changed your treatment strategy based on lymph node analysis?
Response From D.J. Sugarbaker:
In terms of the perioperative mortality of 5%, and a 5-year survival of 14%, you know, if everybody who is in this audience doesn't get up and cheer at 14% for mesothelioma at 5 years, that's okay. I understand. But when you look at some of the other thoracic malignancies that we care for, such as esophageal cancer, pancoast tumors, we are in that range at the current time with mesothelioma. We weren't always there, with virtually nobody surviving past 1 year if you look at the early data.
I would say that one thing that we don't see in our analysis of mortality is that we don't see the 30-to 90-day mortality rate, particularly if they are discharged from the hospital, they are not there. And from our look at that, that's going to be about 4% to 7%, depending upon the subset. I think when you take that into account, it is a big operation. The 5% perioperative mortality rate, I think, needs to be dropped into that context.
In terms of how we have changed our approach, and the answer is, we have. In about 2006, when we had some maturity to our data, we began to do routine mediastinoscopy. We do miss a fair percentage of extrapleural nodes, particularly the periesophageal nodes, low subcarinal nodes, and peridiaphragmatic nodes.
So, the current biopsy techniques are not perfect. Mesothelioma doesn't have the same biologic or pathophysiologic lymph node drainage system. Many of the lymphatics drain directly from the diaphragm and the diaphragmatic pleura to the N2 nodes. They don't go through N1 nodes. They may extend directly, almost as N1 first station nodes, to the periesophageal region. I think that's why there's some confusion about N1, N2, combined N1-N2, and what does it really mean? We hope today to have elucidated the answer to that just a little bit, or at least put light on the question.
